In combination with anti-PD-1, chitin treatment alleviates ICB resistance and further stimulates primary tumor as well as lymphoid anti-tumor immunity, additionally reducing primary tumor growth and lung metastasis. This evidence concerns the gene PDCD1 and neoplasm.